This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.

Transient receptor potential melastatin 3

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Transient Receptor Potential Melastatin 3 or TRPM3 is a non-selective ion channel permeable to both calcium and magnesium. Impaired activity of TRPM3 function is a potential biomarker for ME/CFS.[1] TRPM3 may also be used to refer to the gene for TRPM3.

Function

Members of the Transient Receptor Potential family, including TRPM3, are cation-selective channel proteins which allow the transport of cations across cell membranes into cells.[2] Calcium plays a crucial role in cellular processes, and the importance of TRP proteins in brain homeostasis and dysregulation in pathology is well-known.[3] Structurally, TRP proteins consist of four adjacent subunits which form pores for ion transport. The Transient Receptor Potential Melastatin subfamily is a subdivision of TRPs with identified roles in regulating senses, including vision (TRPM1), taste (TRPM5), and nociception (TRPM2, TRPM3, TRPM8).[4] In comparison, TRPM3 is less well-studied in terms of function, but mutations in the protein have been increasingly recognized as playing a role in developmental and epileptic encephalopathies. Of note, TRPM3 has many subunit-forming isoforms, which are variants produced by alternative splicing of exons from the mRNA transcribed from the Trpm3 gene. Characterization of the TRPM3 proteoform family is difficult due to the number of variants, with different combinations of subunits altering permability and selectivity for ions such as calcium, magnesium, zinc, and other molecules which serve as agonists or antagonists.[4]

ME/CFS

Notable studies

  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[5] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[1] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[6] - (Abstract)
  • 2016, Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[9] - (Full text)
  • 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[10] - [http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0859-z (Full text)
  • 2016, Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients[11] - (Full text)
  • 2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients][12] - (Abstract) - small study - 115 people with ME/CFS
  • 2015, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis[13] - [https://onlinelibrary.wiley.com/doi/10.1111/sji.12388/abstract (Abstract)

News and blogs

See also

Learn more

References

  1. ↑ 1.0 1.1 Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (14). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  2. ↑ https://www.ncbi.nlm.nih.gov/gene/80036https://www.ncbi.nlm.nih.gov/gene/80036
  3. ↑ https://journals.sagepub.com/doi/10.1089/ars.2010.3359
  4. ↑ 4.0 4.1 https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.635659/full
  5. ↑ Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  6. ↑ Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  7. ↑ Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in Natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (2). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551. PMC 6092868. PMID 30134818.
  8. ↑ Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  9. ↑ Marshall-Gradisnik, S.M.; Chacko, A.; Johnston, S.; Smith, P.; Nilius, B.; Staines, D.R. (January 1, 2016). "Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients". Immunology and Immunogenetics Insights. 8: III.S37042. doi:10.4137/III.S37042. ISSN 1178-6345.
  10. ↑ Huth, Teilah Kathryn; Staines, Donald; Marshall-Gradisnik, Sonya (April 21, 2016). "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Journal of Translational Medicine. 14 (1): 97. doi:10.1186/s12967-016-0859-z. ISSN 1479-5876. PMC 4839077. PMID 27098723.
  11. ↑ Nguyen, T.; Staines, D.; Nilius, B.; Smith, P.; Marshall-Gradisnik, S. (May 31, 2016). "Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients". Biological Research. 49 (1): 27. doi:10.1186/s40659-016-0087-2. ISSN 0717-6287. PMC 4888729. PMID 27245705.
  12. ↑ Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (January 1, 2015). "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients". Immunology and Immunogenetics Insights. 7: III.S25147. doi:10.4137/III.S25147. ISSN 1178-6345.
  13. ↑ Huth, T.K.; Brenu, E.W.; Ramos, S.; Nguyen, T.; Broadley, S.; Staines, D.; Marshall‐Gradisnik, S. (2016). "Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis". Scandinavian Journal of Immunology. 83 (1): 44–51. doi:10.1111/sji.12388. ISSN 1365-3083.
Retrieved from "https://me-pedia.org/w/index.php?title=Transient_receptor_potential_melastatin_3&oldid=245029"